Coloplast downgrades organic growth guidance
The medtech firm has announced a smaller adjustment to its full-year outlook for organic growth, going to 6–7% from 7%, due to the pandemic’s impact in China.
by christopher due karlsson, translated by daniel pedersen
Danish medtech firm Coloplast has released figures for the second quarter of fiscal 2021/2022, as well as a downgrade to the firm’s organic growth guidance.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Analyst predicts favorable market conditions for Coloplast
For subscribers
